Advertisement
Organisation › Details
Fluidigm (Group)
Fluidigm (Nasdaq:FLDM) focuses on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, plant and animal research, and clinical laboratories worldwide. Together with them, we strive to increase the quality of life for all. *
Start | 2001-07-02 existent | |
End | 2022-04-04 renamed | |
Group | Standard BioTools (Group) | |
Today | Standard BioTools (Group) | |
Successor | Standard BioTools (Group) | |
Industry | microfluidics technology | |
Person | Linthwaite, S. Christopher (Chris) (Fluidigm 201610– CEO joined 201608 as COO before Thermo Fisher + Life Technologies) | |
Person 2 | Jog, Vikram (Fluidigm 200802– CFO before XDx CFO + Applera) | |
Region | South San Francisco, CA | |
Country | United States (USA) | |
Street | 7000 Shoreline Court Suite 100 | |
City | 94080 South San Francisco, CA | |
Tel | +1-650-266-6000 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | n. a. |
Currency | USD | |
Annual sales | 117,243,000 (revenue, total, consolidated (2019) 2019-12-31) | |
Profit | -64,790,000 (2019-12-31) | |
Cash | 49,600,000 (2020-03-31) | |
* Document for »About Section«: Fluidigm Corporation. (4/1/22). "Press Release: Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion". South San Francisco, CA. | ||
Record changed: 2024-08-12 |
Advertisement
More documents for Standard BioTools (Group)
- [1] Standard BioTools Inc.. (8/6/24). "Press Release: Standard BioTools to Participate in Upcoming Investor Conferences". South San Francisco, CA....
- [2] Standard BioTools Inc.. (1/5/24). "Press Release: Standard BioTools Completes Merger with SomaLogic, Creating a Diversified and Scaled Leader in Life Sciences Tools". South San Francisco, CA & Boulder, CO....
- [3] Standard BioTools Inc.. (10/4/23). "Press Release: Standard BioTools and SomaLogic to Combine in All-Stock Merger Creating a Diversified Leader in Life Sciences Tools". South San Francisco, CA & Boulder, CO....
- [4] Fluidigm Corporation. (4/4/22). "Press Release: Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.". South San Francisco, CA....
- [5] Fluidigm Corporation. (4/1/22). "Press Release: Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion". South San Francisco, CA....
- [6] Fluidigm Corporation. (3/28/22). "Press Release: Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution". South San Francisco, CA....
- [7] Fluidigm Corporation. (1/24/22). "Press Release: Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.". South San Francisco, CA....
- [8] Fluidigm Corporation. (9/2/21). "Press Release: Fluidigm to Participate in the Cantor Virtual Global Healthcare Conference". South San Francisco, CA....
- [9] SomaLogic, Inc.. (12/22/20). "Press Release: SomaLogic Adds $81M to Series A Financing Totaling $214M". Boulder, CO....
- [10] Fluidigm Corporation. (5/7/20). "Press Release: Fluidigm Expands Accessibility of Mass Cytometry and Imaging Mass Cytometry Technology with New Therapeutic Insights Services". South San Francisco, CA....
To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com
Advertisement
» top